Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae266 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von David B Meya und 14 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: Meningitis, Cryptococcal, Amphotericin B, Antifungal Agents, Antigens, Fungal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCATS NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
Cryptococcal meningitis is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) predicts the development of meningitis. Historically, despite standard- of-care fluconazole, 25%–30% of asymptomatic CrAg-positive persons develop breakthrough meningitis or death. We evaluated whether adding single high-dose liposomal amphotericin B to standard pre-emptive fluconazole therapy could improve meningitis-free survival.
Methods
Participants with human immunodeficiency virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with fluconazole or fluconazole alone through 24 weeks. We compared 24-week, meningitis-free survival time between treatment groups. After the second interim review, the Data Safety and Monitoring Board recommended no further enrollment of participants with low plasma CrAg lateral flow assay titers (≤1:80) due to futility. Herein, we present the results of participants with low plasma CrAg titers.
Results
168 participants enrolled into the ACACIA trial had low plasma CrAg titers (≤1:80). During 24 weeks of follow-up, meningitis or death occurred in 14.5% (12/83) of participants randomized to liposomal amphotericin B with fluconazole versus 10.6% (9/85) assigned to fluconazole alone (hazard ratio, 1.42; 95% CI, .60–3.36; P = .431). Adverse events were more frequent in participants assigned to the intervention versus standard-of-care (28% vs 12%; P = .011).
Conclusions
Among CrAg-positive persons with low titers (≤1:80), the addition of single-dose liposomal amphotericin B to fluconazole as pre-emptive therapy provided no additional clinical benefit. This trial provides supportive evidence that, in asymptomatic populations with low plasma CrAg titers, lumbar punctures are likely unnecessary as administration of meningitis treatment did not improve outcomes. Clinical Trials Registration Clinicaltrials.gov (NCT03945448).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
- Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- Division of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: David B Meya, Nicole Engen, Radha Rajasingham
Förderung
- NIAID NIH HHS
- NCATS NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of Neurologic Disorders
- NIH HHS
- FIC NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
Zitieren
APA
Meya, D. B., Nalintya, E., Skipper, C. P., Kirumira, P., Ayebare, P., Naluyima, R., Namuli, T., Turya, F., Walukaga, S., Engen, N., Hullsiek, K. H., Wele, A., Dai, B., Boulware, D. R., & Rajasingham, R. (2025). Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae266
Vancouver
Meya DB, Nalintya E, Skipper CP, Kirumira P, Ayebare P, Naluyima R, et al. Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae266
BibTeX
@article{Meya2025,
author = {Meya, David B and Nalintya, Elizabeth and Skipper, Caleb P and Kirumira, Paul and Ayebare, Peruth and Naluyima, Rose and Namuli, Teopista and Turya, Fred and Walukaga, Stewart and Engen, Nicole and Hullsiek, Kathy H and Wele, Abduljewad and Dai, Biyue and Boulware, David R and Rajasingham, Radha},
title = {Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With HIV–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen Titers},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae266}
}
EUVIMED